The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity

The Food and Drug Administration has approved several pharmacotherapies for the treatment of obesity. This study assesses the cost‐effectiveness of six pharmacotherapies and lifestyle intervention for people with mild obesity (body mass indices [BMIs] 30 to 35).

[1]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[2]  C. Apovian,et al.  Updates on obesity pharmacotherapy , 2018, Annals of the New York Academy of Sciences.

[3]  E. Finkelstein,et al.  Incremental cost‐effectiveness of evidence‐based non‐surgical weight loss strategies , 2019, Clinical obesity.

[4]  Jay R. Desai,et al.  Safety and Effectiveness of Longer‐Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort , 2019, Obesity.

[5]  K. Boye,et al.  The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  F. Greenway,et al.  Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.

[7]  P. O'Neil,et al.  Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial , 2018, The Lancet.

[8]  Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States , 2018, Diabetes Therapy.

[9]  C. Apovian,et al.  Pharmacological management of obesity: an endocrine Society clinical practice guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[10]  C. Mantzoros,et al.  Pharmacotherapy of obesity: Available medications and drugs under investigation. , 2019, Metabolism: clinical and experimental.

[11]  Morton B. Brown,et al.  The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS , 2013 .

[12]  M. N. Oliver,et al.  Lorcaserin (belviq) for weight loss. , 2014, American family physician.

[13]  Crystal M. Riley,et al.  Young adult weight trajectories through midlife by body mass category , 2013, Obesity.

[14]  L. Igel,et al.  Practical Use of Pharmacotherapy for Obesity. , 2017, Gastroenterology.

[15]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[16]  E. Finkelstein,et al.  Cost-Effectiveness Analysis of Qsymia for Weight Loss , 2014, PharmacoEconomics.

[17]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[18]  K. Muir,et al.  The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D , 2007, International Journal of Obesity.

[19]  E. Finkelstein,et al.  Annual medical spending attributable to obesity: payer-and service-specific estimates. , 2009, Health affairs.

[20]  A. Schwartz,et al.  Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study , 2014, Obesity.

[21]  Ping Zhang,et al.  The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention , 2012, Diabetes Care.

[22]  C. Meyerhoefer,et al.  The Medical Care Costs of Obesity: an Instrumental Variables Approach , 2010, Journal of health economics.

[23]  G. Bray,et al.  Medical Therapy for the Patient With Obesity , 2012, Circulation.

[24]  Robert F Kushner,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[25]  K. Gadde,et al.  Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults , 2013, Obesity.

[26]  C. Lavie,et al.  Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , 2009, Journal of the American College of Cardiology.

[27]  George A. Bray,et al.  Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study , 2006, Diabetes & vascular disease research.

[28]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[29]  L. Igel,et al.  Obesity Pharmacotherapy. , 2018, The Medical clinics of North America.

[30]  A. D'Angelo,et al.  Comparison of orlistat treatment and placebo in obese type 2 diabetic patients , 2010, Expert opinion on pharmacotherapy.

[31]  Michael D. Jensen,et al.  Reprint: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[32]  E. Feuer,et al.  Derivation of Background Mortality by Smoking and Obesity in Cancer Simulation Models , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[33]  F. Hu,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[34]  N. Iyer,et al.  Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective , 2018, ClinicoEconomics and outcomes research : CEOR.

[35]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[36]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[37]  A. Avenell,et al.  Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials , 2014, BMJ : British Medical Journal.

[38]  Rena R Wing,et al.  Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. , 2010, Archives of internal medicine.

[39]  A. Wolf,et al.  Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland , 2005, International Journal of Obesity.

[40]  N. Weissman,et al.  Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.

[41]  K. Gadde,et al.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.

[42]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[43]  H. Kang,et al.  Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People , 2006, Yonsei medical journal.

[44]  J. Chhatwal,et al.  Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity , 2017, JAMA surgery.